Sponsors (6)
The bill trades stronger, earlier transparency and regulatory visibility to prevent drug shortages and protect patient care against greater reporting burdens, commercial confidentiality and security risks, and potential cost pressures on manufacturers that could affect prices or supply incentives.
Patients who rely on life‑sustaining drugs, hospitals, and clinicians gain earlier and more actionable warnings about impending drug shortages because manufacturers must notify FDA on accelerated timelines and provide twice‑yearly supply‑chain reports, allowing clinicians and pharmacies to find alternatives and adjust therapy sooner.
FDA and other regulators receive more detailed, actionable supply‑chain information (API sources, supplier identity, production quantities, alternative sources, expected durations), improving regulatory oversight, contamination/quality responses, and planning for shortage mitigation.
Patients, hospitals, and health systems face less economic disruption from drug shortages because improved transparency and regular reporting make proactive supply diversification and emergency actions more feasible.
Manufacturers and suppliers face increased compliance and reporting costs from the new notification timelines and detailed twice‑yearly disclosures, which could raise drug prices or discourage production of low‑margin products.
Manufacturers and suppliers risk exposure of proprietary or commercially sensitive information (API sources, supplier identities, production volumes and alternatives), creating legal/competitive concerns and potential reluctance to share or invest.
Expanded collection and centralization of detailed supply‑chain data increases the risk that sensitive information could be exposed or misused, creating economic or national‑security vulnerabilities if not robustly protected.
Based on analysis of 3 sections of legislative text.
Expands and speeds FDA reporting on drug/API supply disruptions and mandates twice-yearly supplier disclosures with supplier names and quantities.
Requires drug makers and registrants to give FDA more and faster information about supply problems, active pharmaceutical ingredient (API) sources, and supplier identities so the agency can spot and share potential shortages sooner. It tightens notification timing for imminent disruptions, adds a special 10-business-day notice for certain situations, keeps the existing six-month advance notice requirement when possible, and expands FDA’s ability to publish information about disruptions affecting covered drugs. Also requires drug establishments to file two mandatory supply-chain reports each year (March and September) with detailed supplier names and amounts of drug produced using each API or intermediate, while allowing voluntary updates between reports. The definition of “covered drug” is amended to exclude biological products unless FDA later includes them by regulation.
Introduced August 1, 2025 by Amy Klobuchar · Last progress August 1, 2025